Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

34
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
34
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

104
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
104
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

240
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
240
Time Course of Drug Effect01:14

Time Course of Drug Effect

2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution01:09

One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution

227
The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated...
227
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

621
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
621

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Oligonucleotide Ligation Assay (OLA)-Simple: Field Implementation, Usability, and Performance of a near Point-of-Care HIV Drug Resistance Assay in Kenya.

Laboratories·2026
Same author

A Community-Based, Multidisciplinary Training Program to Improve HIV Services for US-Based African Immigrants: Lessons Learned over 5 Years of Implementation.

International journal of environmental research and public health·2026
Same author

The dolutegravir failure cohort: A multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocol.

PloS one·2026
Same author

HIV Status and COVID-19 Treatment Disparities in the US National Clinical Cohort Collaborative.

Open forum infectious diseases·2026
Same author

Associations between recent intimate partner violence and sustained viral suppression among pregnant and postpartum women living with HIV in western Kenya: A secondary analysis of a prospective cohort (Opt4Mamas).

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2025
Same author

Machine learning-optimized perinatal depression screening: Maximum impact, minimal burden.

medRxiv : the preprint server for health sciences·2025

相关实验视频

Updated: Jun 14, 2025

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

8.9K

一个基于生理学的药理动力学模拟,以评估缓解efavirenz诱导的Levonorgestrel暴露下降的方法,使用避孕植入物进行避孕.

Lilian W Adeojo1, Rena C Patel2, Nancy C Sambol1

  • 1Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, University of California San Francisco, San Francisco, CA 94143-0912, USA.

Pharmaceutics
|August 29, 2024
PubMed
概括

为了提高避孕疗效,增加两倍的Levonorgestrel植入剂量,特别是Efavirenz,可能会抵消药物相互作用. 这种方法有助于维持有效的levonorgestrel水平,当与efavirenz.

关键词:
在PBPK模型中,药物相互作用 药物相互作用埃法维伦兹 (efavirenz) 是一种激素避孕药是一种激素避孕药.莱沃诺格斯特雷尔是什么意思药物动力学 药物动力学身体生理学生理学结合等离子体蛋白质的结合.模拟模拟是指一个模拟模拟.

更多相关视频

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

470
Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

1.9K

相关实验视频

Last Updated: Jun 14, 2025

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

8.9K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

470
Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

1.9K

科学领域:

  • 药理动力学 药理动力学
  • 药物相互作用 药物相互作用
  • 避孕药是一种避孕药,用于避孕.

背景情况:

  • 勒沃诺格斯特雷尔植入物是有效的避孕药.
  • 埃法维伦兹是一种细胞染色体酶诱导剂,可以降低勒格斯特勒的疗效.
  • 缓解这种药物相互作用对于保持避孕药的有效性至关重要.

研究的目的:

  • 评估缓解Levonorgestrel植入物和Efavirenz之间的药物相互作用的方法.
  • 评估改变剂量和其他因素对药物度的影响.

主要方法:

  • 使用了基于生理学的药理动力学 (PBPK) 模型来测试levonorgestrel.
  • 模拟了较高的levonorgestrel剂量,较低的efavirenz剂量和组合策略.
  • 研究了血蛋白结合变化和efavirenz暴露变异性的影响.

主要成果:

  • 标准的levonorgestrel剂量与efavirenz显著降低预测度.
  • 两倍的Levonorgestrel植入剂剂量增加了度到控制水平.
  • 降低蛋白质结合减少了总的勒沃诺格斯特勒;较高的埃法维伦兹降低了总和未结合度.

结论:

  • 增加两倍的Levonorgestrel植入剂剂量,特别是400毫克的埃法维伦兹,可能会减轻相互作用.
  • 血蛋白结合和efavirenz代谢的变化可能会影响临床结果.
  • 需要进一步的研究来验证模型的预测与临床数据.